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Key Points
•CB-VSTs can be feasi-
bly generated and are
safe.
•CB-VSTs persist long
term after infusion in
CBT recipients.
Adoptive transfer of virus-speciﬁc T cells (VSTs) has been shown to be safe and effective in
stem cell transplant recipients. However, the lack of virus-experienced T cells in donor
cord blood (CB) has prevented the development of ex vivo expanded donor-derived VSTs
for recipients of this stem cell source. Here we evaluated the feasibility and safety of
ex vivo expansion of CB T cells from the 20% fraction of the CB unit in pediatric patients
receiving a single CB transplant (CBT). In 2 clinical trials conducted at 2 separate sites, we
manufactured CB-derived multivirus-speciﬁc T cells (CB-VSTs) targeting Epstein-Barr virus
(EBV), adenovirus, and cytomegalovirus (CMV) for 18 (86%) of 21 patients demonstrating
feasibility. Manufacturing for 2 CB-VSTs failed to meet lot release because of insuﬃcient
cell recovery, and there was 1 sterility breach during separation of the frozen 20% fraction.
Delayed engraftment was not observed in patients who received the remaining 80%
fraction for the primary CBT. There was no grade 3 to 4 acute graft-versus-host disease
(GVHD) associatedwith the infusion of CB-VSTs. None of the 7 patients who received CB-VSTs
as prophylaxis developed end-organ disease from CMV, EBV, or adenovirus. In 7 patients
receiving CB-VSTs for viral reactivation or infection, only 1 patient developed end-organ
viral disease, which was in an immune privileged site (CMV retinitis) and occurred after
steroid therapy for GVHD. Finally, we demonstrated the long-term persistence of adoptively
transferred CB-VSTs using T-cell receptor-Vb clonotype tracking, suggesting that CB-VSTs
are a feasible addition to antiviral pharmacotherapy.
Introduction
Over the last 25 years, adoptive immunotherapy using virus-specific T cells (VSTs) has emerged as
a safe and effective alternative to antiviral pharmacotherapy.1-5 Although traditional antiviral therapies for
patients after bone marrow or cord blood transplant (CBT) can be costly, ineffective, and often
associated with myelosuppression and renal failure, antiviral T-cell infusions (currently in pivotal phase 3
trials) are safe, effective, and have long-term persistence in vivo.6-11 One limitation of ex vivo generation
of antiviral T cells is the need for the donor to have had prior exposure to the virus, which renders the
approach unsuitable for CBT when the graft T cells are virus naı¨ve.12 Third-party, off-the-shelf allogeneic
T cells are effective for patients who cannot tolerate conventional antiviral pharmacotherapy,13,14 but
studies have shown that persistence of these cells is sustained for only approximately 12 weeks.15
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Hence, third-party VSTs may not provide the required long-term
protection after CBT when full immune reconstitution can be
delayed for as long as 2 years. It would therefore be advantageous
to develop a donor-derived CB-VST product to infuse after CBT
to rapidly restore long-term immune reconstitution in high-risk
patients.16-20
CB contains predominantly naı¨ve T cells,21 which makes the ex vivo
generation of VSTs difficult and thus delays translation to the
bedside. Sun et al22 and Park et al23 reported the generation of
Epstein-Barr virus (EBV)– and cytomegalovirus (CMV)-specific
T cells from CB but not in sufficient doses for clinical application.
In 2009, we published the first Good Manufacturing Practice–
applicable approach to manufacturing CMV-, EBV-, and adenovirus-
specific T cells from CB using 20% of a fractionated CB unit.12,24
However, because low CD341 cell counts in CB units contribute to
delayed engraftment when compared with bone marrow or peripheral
blood stem cell transplants,25 it was not known whether infusing only
80% of the CBT might cause delayed engraftment, which makes this
strategy unfeasible. Moreover, the safety and efficacy of adoptively
transferred naı¨ve-derived T cells have been largely studied in murine
models.26,27 Thus, in contrast to the well-established safety and
efficacy of memory-derived VSTs from peripheral blood, clinical
trials using human naı¨ve–derived T cells are sparse, and little is
known about the long-term safety and efficacy of CB-derived
VSTs (CB-VSTs).
Previously, we showed that by using professional antigen-presenting
cells (APCs) and cytokines to mimic in vivo priming conditions of
naı¨ve T cells, we could expand CMV-, EBV-, and adenovirus-specific
T cells from CB and CMV-naı¨ve adult donors.28 Interestingly, these
cells recognized atypical epitopes of the CMV immunogenic antigen
pp65,12 and it was unknown whether T cells derived from the naı¨ve
population that recognized atypical epitopes would be effective. On
the basis of our preclinical data, we hypothesized that (1) the 20%
fraction derived from the whole CB unit transplanted to the patient
could be used to expand VSTs, (2) the use of this fraction from
adequately sized CB units would not delay engraftment, and (3)
despite their atypical epitope recognition, VSTs from CB could
effectively treat or prevent viral infections after CBT.
To test these hypotheses, we established a clinical trial entitled
“Adoptive Transfer of Cord Blood T Cells to Prevent and Treat CMV
and Adenovirus Infections after Transplantation” (ACT-CAT). Four
years later, ACT-CAT2 was initiated with modified manufacturing
to eliminate gene-modified APCs by using overlapping peptide
libraries targeting 2 immunodominant antigens from each of the
3 targeted viruses (CMV, EBV, and adenovirus). We showed that
adoptive transfer of CB-derived T cells to 14 patients after CBT
was safe and effective in preventing viral disease in the highest-
risk patients and that the infused cells could persist long term as
evaluated by using T-cell receptor-Vb (TCR-Vb) sequencing.
Methods
Patient eligibility
Patients with either malignant or nonmalignant disease undergoing
4/6-6/6 HLA matched unrelated CBT and at high risk for or with
CMV, EBV, or adenovirus reactivation or disease were eligible
for enrollment in ACT-CAT (NCT00880789) and ACT-CAT2
(NCT01923766) at the participating institutions. Risk for CMV, EBV,
or adenovirus reactivation was determined by the treating physician
after considering history of viral exposure or seropositivity, use of
serotherapy in the conditioning regimen, and history of immunode-
ficiency. All the transplant patients were recipients of a single CB
graft. All patients had CB units that were formatted into 2 fractions
with the transplant component (80% fraction) containing a minimum
of 2.5 3 107 total nucleated cells per patient weight in kilograms
(TNCs/kg). The remaining 20% fraction was used for VST gener-
ation. Eligibility for VST infusion required an absolute neutrophil
count .0.5 3 109/L with predominant donor cell chimerism, no
grade 2 to 4 acute graft-versus-host disease (GVHD), and receipt
of #0.5 mg/kg per day prednisone equivalent systemic steroid
therapy at the time of enrollment. Patients with primary disease
relapse were not eligible.
Generation of CB-VST cell cultures
CB-VSTs were generated from licensed or unlicensed frozen
CB units under an investigational new drug application (IND) from
National Marrow Donor Program CB banks. For patients enrolled
on the ACT-CAT clinical trial at Baylor College of Medicine or
ACT-CAT2 at Children’s National Medical Center, the 80% fraction
of the clinical CB unit was infused in the patient as specified by the
transplantation protocol. The 20% fraction of the unit was used to
manufacture CB-VSTs according to the INDs with the US Food and
Drug Administration and as detailed below and in Figure 1. The
INDs held at Baylor College of Medicine and Children’s National
Medical Center were reviewed by the Food and Drug Adminis-
tration and approved by the institutional review boards of each
respective institution. Participants or guardians gave informed
consent upon enrollment.
Generation of dendritic cells from CB
mononuclear cells
To generate the source of APCs for the first T-cell stimulation,
CB was thawed at 37°C, centrifuged at 450g for 10 minutes, and
resuspended in RPMI 1640. CB mononuclear cells (CBMCs) were
then isolated by Ficoll (Lymphoprep; Nycomed, Oslo, Norway)
gradient separation. CBMCs were washed twice, resuspended
in CellGenix media (CellGenix USA, Antioch, IL), and plated at
approximately 1 3 107 cells per mL in 2 mL of dendritic cell (DC)
medium (CellGenix media plus 2 mM L-glutamine) (GlutaMAX;
Invitrogen, Carlsbad, CA) in a 6-well plate (Costar, Corning, NY)
for 1 to 2 hours at 37°C in a humidified CO2 incubator. Nonadherent
cells were removed by rinsing with 13 phosphate-buffered saline
(Sigma, St. Louis, MO) and cryopreserved for later use. Cells adher-
ent after 1 to 2 hours were cultured in DC media with 800 U/mL
granulocyte-macrophage colony-stimulating factor (Sargramostim
Leukine; Immunex, Seattle, WA) and 500 U/mL interleukin-4 (IL-4)
(R&D Systems, Minneapolis, MN) for 5 days. On day 5, the cells
were matured as described below.
Maturation of DCs and transduction with Ad5f35-pp65
vector (ACT-CAT)
CB-derived DCs were transduced with a chimeric adenoviral vector
expressing the immunodominant CMVpp65 antigen (Ad5f35-pp65)29
at a multiplicity of infection of 1000 viral particles on day 512 and
matured using a cytokine cocktail consisting of 800 U/mL granulocyte-
macrophage colony-stimulating factor, 1000 U/mL IL-4, 10 ng/mL
IL-1b, 10 ng/mL tumor necrosis factor-a, 100 ng/mL IL-6 (R&D
Systems), and 1 mg/mL prostaglandin E1 (Sigma) (cytokine cocktail)
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for 1 to 2 days. On days 6 to 7, the DCs were harvested and used to
stimulate T cells present in the cryopreserved nonadherent fraction.
Maturation and peptide pulsing of DCs (ACT-CAT2)
CB DCs were generated as described above, but instead of
adenoviral vector transduction, they were pulsed with viral PepMix
libraries containing overlapping 15mer peptides (JPT, Berlin, Germany)
encompassing viral antigens IE-1 and pp65 (CMV), LMP2 and EBNA1
(EBV), and hexon and penton (adenovirus).30 At the time of maturation,
the same maturation cocktail was used as above but with the addition
of 30 ng/mL lipopolysaccharide. On days 6 to 7, the mature DCs were
harvested, centrifuged at 400g for 5 minutes, pulsed with 100 ng
peptide master mix per 10 million DCs for 30 to 60 minutes, and
then plated in T-cell medium containing human serum in a 24-well
plate at approximately 1 to 2 3 105 cells per well.
Generation and adenoviral transduction of
EBV-transformed B-cell lines from CBMCs
Because CB-VSTs are generated from a naı¨ve T-cell donor source,
multiple stimulations are needed to ensure sufficient cell yield and
specificity.12,28 CB-derived DCs were required for T-cell priming
(first stimulation), and lymphoblastoid cell lines (LCLs) were used
to expand the CB-derived VSTs (second and third stimulations). To
generate LCLs, 5 3 106 CBMCs were infected at the time of DC
plating with supernatants from an EBV-producing B95-8 working
cell bank.3 Once the LCLs were established, sufficient LCLs were
either transduced with the Ad5f35-pp65 vector (ACT-CAT)12 or
pulsed with overlapping peptide libraries (ACT-CAT2) as previously
described.31
T-cell initiation and stimulations
At the time of initiation, the nonadherent cells that were collected
during the generation of DCs were thawed and washed, and
2 million nonadherent cells were added to each well of a 24-well
plate for a T-cell:DC ratio of approximately 1:10 to 1:20. Then,
10 ng/mL IL-7, 10 ng/mL IL-12, and 5 ng/mL IL-15 were added to
the T-cell media–containing human serum. After 9 to 12 days, the
T cells were again cryopreserved until the EBV LCLs were
sufficiently expanded. T cells were then added to either 24-well
plates at a T-cell:LCL ratio of 4:1 or to Grex10 devices at 5:1 in
the presence of 5 ng/mL IL-15. This was again repeated for the
third stimulation, with IL-2 being substituted for IL-15. After the
second stimulation, cells were fed every 3 to 4 days with 50 to
100 U/mL IL-2.
Product release
All T cells were released under a certificate of analysis after
appropriate testing was completed. Release testing was as
follows: ,2% CD3–/CD831; ,2% CD19; .70% viable by
Trypan blue; negative for Mycoplasma; ,5.0 EU/mL endotoxin;
sterile for anaerobic/aerobic bacteria at 4 days or 21 days,
sterile for fungus at 21 or 28 days; and ,10% killing of patient
or related-donor phytohemagglutinin blasts in a chromium-release
cytotoxicity assay.
Antigen-expressing DCs +
nonadherent cells (T cells)
+ IL7, IL12, IL15
Antigen-expressing EBV
LCL + expanded T cells +
IL15/IL2
Antigen-expressing EBV
LCL + expanded T cells +
IL2
T Cell Initiation
Day 7
3rd T Cell Stimulation
Day 24
2nd T Cell Stimulation
Day 17
T Cell Cryopreservation
Day 31
80%
20 mL
20%
5 mL
EBV LCL
Monocyte-derived dendritic cells
Non-adherent cells
(containing T cells)
Figure 1. Schematic of CB-VST manufacture in ACT-CAT and ACTCAT2 clinical trials. Eighty percent of the CB unit was used as the CB transplant graft, and 20%
was used to expand the VST. From the 20% fraction, 5 to 10 million peripheral blood mononuclear cells (PBMCs) were used for EBV lymphoblastoid cell line (LCL) generation;
the remaining cells were used to generate dendritic cells (DCs) or used as the source of T cells. DCs were matured and transduced with the Ad5f35-pp65 vector (ACT-CAT)
on day 5 and/or cocultured with overlapping viral peptides (PepMix) (ACT-CAT2), then cocultured with the nonadherent fraction (containing T cells) on day 7 in the presence
of IL-7, IL-12, and IL-15. At the second and third stimulation, EBV-transformed B cells were transduced with the same Ad5f35-pp65 vector 2 days before the T-cell stimulation
or pulsed with PepMix the day of stimulation, which was performed in the presence of IL-15 (second stimulation) and IL-2 (third stimulation).
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Enzyme-linked immunospot assay
Enzyme-linked immunospot (ELISPOT) analysis was used to test
the frequency of CB-VSTs secreting interferon-g (IFN-g) when
stimulated with PepMixes for CMV, EBV, and adenovirus as previ-
ously described.12 Spot-forming cells (SFCs) were enumerated by
Zellnet Consulting (New York, NY) and compared with input cell
numbers to obtain the frequency of virus-reactive T cells.
Immunophenotyping
CB-VSTs were stained and analyzed with monoclonal antibodies to
CD3, CD4, CD8, CD56/16, CD19, CD83, CD45RA, and CD62L
(Becton Dickinson, Franklin Lakes, NJ and Miltenyi Biotec).
TCR sequencing
Frozen peripheral blood samples were obtained from patients
enrolled on ACT-CAT or ACT-CAT2. In some cases, cells were
sorted using magnetic-activated cell sorting selection based
on expression of CD45RA. TCR-Vb sequencing was performed
using the ImmunoSEQ platform from genomic DNA with primers
specific for 45 expressed Vb regions and 13 Jb regions (Adaptive
Biotechnologies, Seattle, WA). In most cases, bulk cytotoxic T
lymphocyte products or patient follow-up peripheral blood mono-
nuclear cell (PBMC) samples were analyzed by Survey level (VST)
or deep T-cell receptor (PBMC) sequencing. Bioinformatic analysis
was performed on the sequencing data using the ImmunoSEQ
platform.32
Clinical trial design and statistical analysis
The 2 phase 1 dose-escalation trials were designed to evaluate
the safety of CB-VSTs with dose escalation guided by the modi-
fied continual reassessment method to determine the maximum
tolerated dose of VSTs.33 Dose-limiting toxicity (DLT) was defined
as the development of National Cancer Institute grade 3 to 4
nonhematologic toxicity that was attributed to the VSTs within
30 days or GVHD within 45 days of infusion. Maximum tolerated
dose was defined as the dose at which the probability of DLT is
at most 21%. For the phase 1 trial, data analyses were mainly
descriptive. Comparisons between groups were performed in
GraphPad PRISM 8.01 using a 2-tailed Student t test assuming
equal variance. P , .05 was considered statistically significant.
Results
Patient and transplant characteristics
Patient demographics and transplant characteristics of the 14
patients (9 on ACT-CAT and 5 on ACT-CAT2) who received
a CB-VST infusion are shown in Table 1. The median age was
23 months (range, 12 months to 8 years), and an equal number
of patients had an underlying malignant or nonmalignant disorder
as the indication for CBT. No patients on ACT-CAT received
alemtuzumab or antithymocyte globulin before transplantation,
whereas 3 of 5 patients in ACT-CAT2 did. Most patients (n5 13)
received cyclosporine and mycophenolate mofetil as part of their
GVHD prophylaxis, and 11 patients received steroids after
transplantation but before CB-VST infusion as GVHD prophylaxis
or treatment of GVHD or engraftment syndrome after the CBT.
Four patients had a 6/6 HLA match (antigen matched for HLA-A
and B, allele matched for HLA-DRB1), 9 had a 5/6 match, and 1
had a 4/6 match. All patients underwent transplantation using
a CB unit from a single unrelated donor.
Feasibility of manufacturing CB-VSTs
Of 21 patients who had VST manufacture initiated on the protocols,
18 patients had VSTs that were successfully manufactured for
clinical use (supplemental Table 1). On ACT-CAT2, manufactur-
ing for 2 VSTs failed to meet lot release because of insufficient
cell recovery, and there was 1 potential contamination during separation
of the 20% fraction. Fourteen of these 18 patients with successfully
generated products were infused with CB-VSTs. Reasons for not
infusing were GVHD (n 5 2; 1 on ACT-CAT and 1 on ACT-CAT2),
death (n 5 1; ACT-CAT2), and family choice (n 5 1; ACT-CAT2).
Overall, the median manufacturing time (from initiation to clinical
freeze and excluding release testing) was 52.5 days (range, 40-111
days). Delays in manufacturing were a result of either slow growth of
EBV LCLs or the requirement to restimulate cryopreserved products.
Including time required for release testing and other variables, the
median time to infusion was 87 days (range, 63-434 days).
Engraftment
The primary transplant used 80% of the CB unit (Figure 1). At
a minimum cell dose for primary transplant of 2.53 107 TNCs/kg,34
all patients engrafted within expected time frames35 with a median
time to neutrophil engraftment of 18 days (range, 11-28 days)
and a median time to platelet engraftment of 51 days (range,
35-66 days).
Product characterization
CB-VSTs were expanded by using APCs transduced with an
Ad5F35-pp65 vector or with APCs pulsed with overlapping peptides
(PepMixes) representing the same viruses. After 3 expansions, the
median number of the CB-VSTs manufactured from each 20%
fraction was 63 107 cells (range, 3.3 to 27.73 107 cells) with higher
cell yields in the peptide-based manufacture (ACT-CAT2) compared
with viral vector–based manufacture (ACT-CAT) (1433 107 vs 433
107 cells; P 5 .001) (Figure 2A). Most VSTs were specific for more
than 1 virus (Figure 2B), with a median SFC of 13 (range, 1-110
SFCs) for CMV-pp65, 19 for Ad-hexon (range, 0-486 SFCs), and 42
for EBV LCLs or EBV-EBNA1/LMP2 (range, 0-339 SFCs). For
products made under ACT-CAT2, PepMixes for EBV-EBNA1, EBV
LMP2, and CMV-IE1 were also evaluated when possible alongside
other PepMixes and EBV LCLs. Expanded cells were composed of
a median of 50% CD31/CD41 (range, 5% to 86% CD31/CD41)
and 32% CD31/CD81 (range, 4% to 79% CD31/CD81) T cells
with negligible CD191 and CD3–/CD831 APCs. Absence of these
defined APCs was a release criterion for both protocols. CB-VSTs
composed a median of 39% (range, 22% to 69%) effector memory
(CD45RA–/CD62L–) and a median of 38% (range, 16% to 74%)
central memory (CD45RA–/CD62L1) T cells (Figure 2C). The
CD45RA1 population was too small to fully characterize.
Safety of CB-VSTs
The ACT-CAT and ACT-CAT2 trials were designed to evaluate 4 dose
levels: 53 106, 1.03 107, 1.53 107, and 2.53 107 cells per m2. In
ACT-CAT, no treatment-related DLT was observed, and the study
dose was escalated as planned after infusion of 2 patients at each
of the first 3 dose levels (5 3 106, 1.0 3 107, and 1.5 3 107 cells
per m2) and concluded after 3 patients were treated at the highest
dose level of 2.53 107 cells per m2 without a DLT. In ACT-CAT2, 4
patients were treated at the first dose level (5 3 106 cells per m2)
followed by escalation to the second dose level at which patients
2060 ABRAHAM et al 23 JULY 2019 x VOLUME 3, NUMBER 14
Ta
b
le
1.
D
em
o
g
ra
p
h
ic
s
o
f
p
at
ie
n
ts
re
ce
iv
in
g
C
B
-d
er
iv
ed
V
S
T
in
fu
si
o
n
s
P
at
ie
n
t
ID
D
ia
g
n
o
si
s
A
g
e,
y
S
ex
W
ei
g
h
t,
kg
C
o
n
d
it
io
n
in
g
re
g
im
en
H
LA
m
at
ch
(o
f
6)
Im
m
u
n
o
su
p
p
re
ss
io
n
b
ef
o
re
V
S
T
R
ec
ip
ie
n
t
C
M
V
se
ro
st
at
u
s
TN
C
s
fr
o
m
U
C
B
,
3
10
7
TN
C
s/
kg
o
f
U
C
B
fr
ac
ti
o
n
u
se
d
fo
r
p
ri
m
ar
y
tr
an
sp
la
n
t
A
C
T-
C
A
T
P
28
91
Fa
nc
on
ia
ne
m
ia
5
M
13
.0
Fl
u/
C
y/
TB
I
5
C
S
A
,M
M
F,
st
er
oi
ds
P
os
iti
ve
16
1
9.
9
P
30
10
A
LL
2
M
11
.0
Fl
u/
C
y/
TB
I
5
C
S
A
,M
M
F
P
os
iti
ve
19
1
13
.9
P
32
75
S
C
ID
1
M
5.
2
B
u/
C
y/
Fl
u
6
C
S
A
,M
M
F,
st
er
oi
ds
P
os
iti
ve
12
1
18
.8
P
33
17
M
ye
lo
fib
ro
si
s
2
M
9.
7
B
u/
C
y/
Fl
u
5
C
S
A
,M
M
F,
st
er
oi
ds
P
os
iti
ve
22
5
18
.6
P
34
57
JM
M
L
2
M
12
.3
B
u/
C
y/
Fl
u
5
C
S
A
,M
M
F
P
os
iti
ve
18
5
12
.0
P
35
31
S
C
ID
1
M
6.
4
B
u/
C
y/
Fl
u
5
C
S
A
,M
M
F,
st
er
oi
ds
P
os
iti
ve
12
9
16
.0
P
35
55
S
C
ID
1
M
8.
0
B
u/
C
y/
Fl
u
6
C
S
A
,M
M
F,
st
er
oi
ds
P
os
iti
ve
11
0
11
.0
P
39
23
A
M
L
1
F
7.
0
B
u/
C
y/
Fl
u
5
C
S
A
,M
M
F,
st
er
oi
ds
P
os
iti
ve
10
2
11
.7
P
36
26
JM
M
L
1
M
9.
0
B
u/
C
y/
Fl
u
5
C
S
A
,M
M
F
P
os
iti
ve
20
9
18
.6
A
C
T-
C
A
T2
P
00
20
A
M
L
3
F
16
.7
B
u/
C
y
5
C
S
A
,M
M
F,
st
er
oi
ds
,E
C
P
P
os
iti
ve
10
3
4.
9
P
00
35
H
ur
le
r’s
sy
nd
ro
m
e
1.
1
F
8.
8
B
u/
Fl
u/
A
TG
/
rit
ux
im
ab
4
C
S
A
,s
te
ro
id
s
P
os
iti
ve
25
2
22
.9
P
00
39
In
fa
nt
A
LL
1.
9
M
12
.2
Fl
u/
C
y/
TB
I
6
C
S
A
,M
M
F,
st
er
oi
ds
P
os
iti
ve
67
4.
4
P
00
67
S
ic
kl
e
ce
ll
di
se
as
e
8
F
19
.8
Fl
u/
M
el
/T
hi
o/
al
em
tu
zu
m
ab
/H
U
6
C
S
A
,M
M
F,
in
fli
xim
ab
,s
te
ro
id
s
P
os
iti
ve
10
9
4.
4
P
01
23
S
ic
kl
e
ce
ll
di
se
as
e
4
M
16
.6
Fl
u/
M
el
/T
hi
o/
al
em
tu
zu
m
ab
/H
U
5
C
S
A
,t
ac
ro
,M
M
F,
st
er
oi
ds
N
eg
at
iv
e
19
7
9.
5
A
LL
,a
cu
te
ly
m
ph
oc
yt
ic
le
uk
em
ia
;A
M
L,
ac
ut
e
m
ye
lo
id
le
uk
em
ia
;A
TG
,a
nt
i-t
hy
m
oc
yt
e
gl
ob
ul
in
;B
u,
bu
su
lfa
n;
C
S
A
,c
yc
lo
sp
or
in
A
;C
y,
cy
cl
op
ho
sp
ha
m
id
e;
EC
P
,e
xt
ra
co
rp
or
ea
lp
ho
to
ph
er
es
is
;F
,f
em
al
e;
Fl
u,
flu
da
ra
bi
ne
;H
LA
,h
um
an
le
uk
oc
yt
e
an
tig
en
;H
U
,h
yd
ro
xy
ur
ea
;J
M
M
L,
ju
ve
ni
le
m
ye
lo
m
on
oc
yt
ic
le
uk
em
ia
;M
,m
al
e;
M
el
,m
el
ph
al
an
;M
M
F,
m
yc
op
he
no
la
te
m
of
et
il;
S
C
ID
,s
ev
er
e
co
m
bi
ne
d
im
m
un
od
ef
ic
ie
nc
y;
ta
cr
o,
ta
cr
ol
im
us
;T
B
I,
to
ta
lb
od
y
irr
ad
ia
tio
n;
Th
io
,t
hi
ot
ep
a;
TN
C
,t
ot
al
nu
cl
ea
te
d
ce
lls
;U
C
B
,u
m
bi
lic
al
co
rd
bl
oo
d.
23 JULY 2019 x VOLUME 3, NUMBER 14 SAFETY AND FEASIBILITY OF CORD BLOOD VSTs 2061
received 1 3 107 cells per m2, and again no treatment-related DLT
was observed. No infusion-related adverse events were observed in
any of the 14 patients treated on either trial. No patient developed
grade 3 to 4 acute GVHD during the 45-day post infusion monitoring
period. One patient (P0067) with improving GVHD at the time of VST
infusion developed grade 3 acute GVHD involving the gastrointes-
tinal tract 53 days after VST; within 4 days of treatment with systemic
steroids, the patient experienced complete resolution of symptoms
and was subsequently weaned off all immunosuppression without
further recurrence.
Viral infections
VSTs were infused at a median of 87 days (range, 48-434 days)
after transplantation (supplemental Table 1). Thirteen of 14 patients
were receiving immunosuppression with a combination of calcineurin
inhibitors, mycophenolate mofetil, or low-dose steroids at the time
of infusion. One patient in the treatment group (P2891) received
3 VST infusions for persistent disease, and 1 in the prophylaxis
group (P0020) received 2 infusions for viral reactivation after the
first infusion (Table 2). Of the 14 patients treated (Table 2), 7 had
detectable low-level viral reactivation or disease within 1 week
before CB-VST infusion. The remaining 7 were deemed to
be at high risk for developing viral disease and received
CB-VST prophylactically. All 7 patients with detectable virus
had a decrease in viral burden after CB-VST infusion. Five
patients cleared the virus at a median of 2 months (range, 1.4-
12 months) after CB-VST. Patient P0067 cleared CMV from
the blood but received steroid therapy after VST infusion for
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GVHD. This patient was subsequently diagnosed with CMV
retinitis 6 months after CB-VST infusion and was taken off
study to receive third-party VSTs because the steroid therapy
for GVHD likely affected CB-VST persistence in vivo. Patient
P3457 continued to have low levels of EBV DNA but did not
develop posttransplant lymphoproliferative disorder and did
not receive additional treatment (eg, anti-CD20 therapy). Of
the 7 patients at high risk for viral infection who received
the CB-VSTs as prophylaxis, no patient developed end organ
disease and only 1 patient (P0020) required additional therapy
(second CB-VST infusion and cidofovir) to treat adenovirus
reactivation in the blood and stool.
Virus-specific immune reconstitution was superior in
patients receiving CB-VSTs at the time of viral
infection or reactivation
VST responses were measured at the time of infusion and
periodically thereafter by interferon-g ELISPOT assay in response
to stimulation with viral antigens (Figure 3A). Figure 3A shows data
from a representative patient (P0039) with CMV reactivation in
which the viral load increases and then clears after an increase in
pp65-specific T cells in the patient’s peripheral blood. Patients who
were treated for active viral infections (n5 7) (Figure 3B) seemed to
have superior VST immune reconstitution at 3 months after infusion
compared with those patients treated prophylactically without viral
infection or reactivation (n 5 7) (Figure 3C).
Long-term persistence of CB-VSTs as detected by
using TCR sequencing
In the absence of gene marking, tracking infused CB-VSTs in
patients is difficult. However, by sequencing TCR clonotypes
present in the CB-VST products, VSTs can be tracked in the
peripheral blood over time on the basis of the presence of
clonotypes associated with the CB-VST product. Figure 4A-C
shows unique clonotypes present in the manufactured VST
product and detected in the patients’ peripheral blood after VST
infusion but not detected in the patients’ peripheral blood
before infusion. As demonstrated in 1 patient (P2891) with viral
infection at the time of infusion, there was an increase in
the frequency of unique clonotypes after infusion of CB-VSTs
(Figure 4A). This was also observed in 2 patients (P3555 and
P3317) with no viral infection at the time of infusion (Figure 4B-C).
We also observed an increase in the na ı¨ve T-cell (CD45RA1)
TCR-Vb diversity over time in 1 patient (P2891) who had CMV
viremia at the time of CB-VST infusion, further supporting
a restoration of immunity with infusion (Figure 4D). The
persistence of TCR clonotypes unique to the CB-VST product
was evident up to 1 year after infusion (Figure 4H), and these
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unique clones persisted regardless of the presence of viral antigen
at the time of infusion (Figure 4I).
Discussion
Here we evaluated the use of CB-VSTs generated from the
20% fraction of CB units used for CBT. Small product volume,
low cell numbers, high percentage of nucleated red blood cells,
and inability to procure further donations have prevented the
widespread use of CB cells as a source of cellular therapy
beyond transplantation. Whereas chimeric antigen receptor
T cells,36 VSTs,37-39 and other cellular therapies generated
from donor PBMCs have recently demonstrated success, to
our knowledge, this is the first clinical study using 20% of a
fractionated CB unit intended for transplant as a means to
augment the graft. In this study, we demonstrated that using the
20% fraction is feasible, results in sufficient expansion of cells
to treat patients on clinical protocols, and may provide clinical
benefit to patients.
Recently, many groups have confirmed the efficacy of antiviral
T cells from seropositive donors. Such antiviral T cells can now
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be manufactured in 10 days40 with products including VSTs
that target up to 6 viruses41 in a single culture. By using these
approaches, the overall response rate has exceeded 90%.38 For
more rapid cultures, Peggs and colleagues42 showed that it was
feasible to generate sorted VST products in less than 48 hours
that were safe and efficacious. However, all of these reports
required the donor to be seropositive for each of the viruses
targeted. In this report, we have used CB as the T-cell source,
which contains predominantly virus-naı¨ve T cells. Because the
T cells are derived from the naı¨ve T-cell population, the manufacture
requires additional cytokines, stimulation with professional APCs,
and a longer manufacturing time.
The use of naı¨ve T cells as a source of VSTs has not been extensively
studied, although murine studies suggest that naı¨ve-derived antigen-
specific T cells have superior proliferation, longer telomeres, and
better function than certain memory-derived T cells.26,27 Although
this may be true in vivo, it is important to note that the ex vivo
expansion of T cells can be difficult, especially given the limited
starting volume and cell number. Nevertheless, the required cell
dose was met for all but 2 patients, in whom there were abnormally
low cell counts before initiating the culture. Without a blinded,
head-to-head trial comparing memory-derived vs naı¨ve-derived
VSTs, it is impossible to determine whether the naı¨ve-derived
T cells are as efficacious. The complexity of the patients receiv-
ing VSTs and the small sample size also make assessing the
efficacy of the T cells difficult. Nevertheless, the ability to gen-
erate donor-derived CB-VSTs that can be administered as
prophylaxis to high-risk patients after CBT to prevent viral
disease and restore antiviral immunity long term is an attractive
approach. Other challenges still remain, such as generating
sufficient expansion to yield adequate cells for large adult
recipients. On the basis of the highest dose level tested in this
study of 2.5 3 107 cells per m2 and a theoretical body surface
area of 2 m2, 100% of patients would have been eligible to
receive CB-VSTs using the optimized manufacturing on the
second trial. With further refinements to the manufacturing
process such as those previously reported as well as a higher
desired manufacturing yield, it is possible that the percentage of
eligible recipients would be higher, although additional optimi-
zation is needed to treat large adult patients. The feasibility of
this will be assessed in our follow-up study (ClinicalTrials.gov
identifier: NCT03594981).31
Previous work by our group indicated that na ı¨ve-derived T cells
recognize atypical epitopes of CMV.12 The CB-VSTs manufac-
tured for our 2 clinical trials were expected to elicit T-cell
responses in vivo that recognize only atypical epitopes of CMV-
pp65. However, the limited volume of blood obtained from the
patients for follow-up testing and the lack of CMV reactivation
or infection in patients for which epitope characterization was
available made evaluating the persistence of these unique T-cell
populations challenging. We plan to perform these analyses in
future clinical trials that treat adult patients with CB-VSTs in
which follow-up patient samples should be adequate. Regard-
less, we did observe the persistence of CMV-specific T-cell
clones by deep TCR sequencing.28
In this study, we demonstrated the feasibility of VST manufac-
ture from the 20% fraction of naı¨ve CB in the majority of patients
enrolled on the study. However, 3 of 21 products failed manufacturing,
and the overall time-to-clinical freeze of 52.5 days remains
an obstacle to widespread adoption of this treatment. Current
approaches for antiviral adoptive cellular therapy require less
than 10 days for ex vivo expansion, with cell selection approaches
requiring less than 2 days. Improvements have been made to
this process, and a 30-day manufacturing method has been
reported,31 but it remains to be seen whether the time can be
reduced to 10 to 14 days and therefore be more readily applica-
ble worldwide instead of limited to specialized individual centers.
In addition, because the CB units are cryopreserved, the VST
products could be manufactured before transplantation and be
available when needed.
In summary, we have demonstrated the safety and feasibility
of using the 20% fraction of fractionated CB units to expand
CB-VSTs for clinical use. When administered to patients after
CBT, CB-VSTs may persist over the long term and restore
antiviral immunity to prevent viral infection or may complement
antiviral pharmacotherapies when administered for the treat-
ment of active CMV, EBV, or adenovirus infection in high-risk
patients.
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